Minovia Therapeutics key facts
as of Oct 2026- Developer of mitochondrial augmentation therapy designed to treat mitochondrial diseases.
- Minovia Therapeutics is valued at approximately $86.3M as of Oct 2026 (last reported valuation).
- It has raised $16.1M; the latest was PIPE ($18.0M) in Jun 2025.
- Notable investors include Vincent Tchenguiz, Countdown for a Cure Foundation, EIT Health, Gold Track, Yozma.
- Status: Privately Held (backing).
Minovia Therapeutics's last reported valuation, Dec 2018. Nothing priced has surfaced since.
- ·Watch Minovia Therapeutics: the Monday email on marks, rounds and moves
Minovia Therapeutics funding rounds
No funding rounds for Minovia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Minovia Therapeutics
5Minovia Therapeutics valuation
Minovia Therapeutics's last reported valuation was $86.3 million in Dec 2018. No priced round, secondary trade or fund mark has surfaced since.
Minovia Therapeutics investors
5 investors are on record for Minovia Therapeutics, including Vincent Tchenguiz, Countdown for a Cure Foundation, EIT Health and Gold Track.
About Minovia Therapeutics
Developer of mitochondrial augmentation therapy designed to treat mitochondrial diseases. The company's platform repairs damaged mitochondrial DNA by using autologous stem cells enriched with blood-derived mitochondria that enrich patients' hematopoietic stem cells with healthy donor mitochondria, compatible assays, and scalable manufacturing, enabling medical practitioners to extend and enhance human lives and to receive personalized treatment that enhances mitochondrial function and supports healthier life outcomes.
- Sector
- Healthcare
- HQ
- Tirat Hacarmel, Israel
- Founded
- 2011
- Employees
- 28
- Website
- minoviatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.